Last reviewed · How we verify
ILT101
At a glance
| Generic name | ILT101 |
|---|---|
| Also known as | low-dose IL-2, IL2 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy (PHASE2)
- Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes (PHASE2)
- Low-dose IL-2 in Established T1D - The "PROREG" Study (PHASE1, PHASE2)
- Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (PHASE2)
- Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers (PHASE1)
- Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 (PHASE2)
- Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases (PHASE2)
- Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ILT101 CI brief — competitive landscape report
- ILT101 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI